← Leaderboards
Mark A. Hlatky
Stanford University
$8,426,433
Attributed
$12,903,937
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,903,937 · 4
By mechanism
R01$9,346,168 · 2
U01$2,558,841 · 1
RC1$998,928 · 1
Top collaborators
- Virginia D Winn4 shared
Most similar at Stanford University
Same institution · by research overlap
- Daria Mochly-Rosen$28,932,521
- Alison L Marsden$14,840,284
- Koen Nieman$5,698,996
- Jason Paul Glotzbach$575,449
- Yu Chen$10,804,934
Others in their field
Top investigators on “Noninsulin Dependent Diabetes Mellitus”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$69,532,406
- Katherine M Detre · University Of Pittsburgh At Pittsburgh$33,288,043
- Mark Andrew Espeland · Wake Forest University Health Sciences$18,466,667
- C Ronald Kahn · Joslin Diabetes Center$17,946,199
- F. Xavier Pi-Sunyer · Columbia University Health Sciences$13,600,448
- David M Nathan · Massachusetts Institute Of Technology$13,352,064
Research focus
Noninsulin Dependent Diabetes MellitusLinkBehavioral /Social Science Research TagBaseCardiovascular SystemClinical ResearchInsulin Sensitivity /ResistanceHuman SubjectCoronary BypassHuman Therapy EvaluationMyocardial Ischemia /HypoxiaAtherosclerosisCooperative StudyHeart RevascularizationInsulinCost EffectivenessDiabetes Mellitus TherapyBlood GlucoseHealth Services Research TagHeart Disorder ChemotherapyHealth EconomicsCohortComputing MethodologiesBiological Markers
Grant awards (14)
Preeclampsia to cardiovascular disease: Life course analysis of biomarkers and risk$2,278,257
R01 · FY2021 · HL · contact PI
Preeclampsia to cardiovascular disease: Life course analysis of biomarkers and risk$2,192,149
R01 · FY2020 · HL · contact PI
Preeclampsia to cardiovascular disease: Life course analysis of biomarkers and risk$2,217,157
R01 · FY2019 · HL · contact PI
Preeclampsia to cardiovascular disease: Life course analysis of biomarkers and risk$2,267,445
R01 · FY2018 · HL · contact PI
Improved Estimates of the Comparative Treatment Effects of CABG and PCI$499,082
RC1 · FY2010 · HL · contact PI
Improved Estimates of the Comparative Treatment Effects of CABG and PCI$499,846
RC1 · FY2009 · HL · contact PI
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$442,468
U01 · FY2006 · HL · contact PI
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$453,116
U01 · FY2005 · HL
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$453,116
U01 · FY2004 · HL
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$305,042
U01 · FY2003 · HL
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$434,458
U01 · FY2002 · HL
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$306,273
U01 · FY2001 · HL
COST AND QUALITY OF LIFE OUTCOMES AFTER PTCA OR CABG$391,160
R01 · FY2000 · HL
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2$164,368
U01 · FY2000 · HL